The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Peptide Reclassification 2026: What It Means for Providers FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner